Abstract: TH-PO739
Racial and Ethnic Minorities Are Poorly Represented in High-Impact Nephrology Trials
Session Information
- Diversity and Equity in Kidney Health - I
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Diversity and Equity in Kidney Health
- 800 Diversity and Equity in Kidney Health
Authors
- Soomro, Qandeel H., NYU Langone Health, New York, New York, United States
- Mccarthy, Angela L., NYU School of Medicine, New York, New York, United States
- Varela, Dalila, NYU School of Medicine, New York, New York, United States
- Keane, Colin Joel, NYU School of Medicine, New York, New York, United States
- Ways, Javaughn Michael, NYU School of Medicine, New York, New York, United States
- Charytan, Amalya M., NYU School of Medicine, New York, New York, United States
- Ramos, Giana Kristy Codilla, NYU Langone Health, New York, New York, United States
- Nicholson, Joey, NYU School of Medicine, New York, New York, United States
- Charytan, David M., NYU Langone Health, New York, New York, United States
Background
Kidney disease disproportionately impacts underrepresented racial and ethnic minorities (URM), but only limited data are available on their representation in kidney disease randomized clinical trials
Methods
We analyzed how frequently race and ethnicity of trial participants were reported as well as trends in enrollment of URM in nephrology RCTs. We systematically identified RCTs between 2000 and 2021 published in 10 high impact journals and extracted data from manuscripts, supplementary material and clinical trials.gov. Race and ethnicity were classified using standard NIH PHS inclusion enrollment form categories. Enrollment of URM and reporting on race and ethnicity were analyzed according to trial type, enrollment site, and publication date
Results
We screened 4494 and identified 370 RCTs meeting inclusion criteria with a total enrollment of 339,047. Participant race was reported in 55% whereas ethnicity was reported in only 12% of RCTs. Among trials reporting race, White participants accounted for 87% of subjects in AKI, 75% of CKD, 62% of dialysis, 42% of glomerulonephritis and 81% of kidney transplant trials whereas Black individuals accounted for <10% of trial subjects with the exception of dialysis trials (26%). Asians accounted for 39% of GN trials-mainly IgA trials. Similarly, in trials reporting race, the majority of participants were White regardless of site but the proportion was lower in US only trials: International 79%, US only 59%, Outside US 76%, Europe only 89.5%. The enrollment trend from 2000-2021 for White participants remained between 75-83%
Conclusion
Despite kidney diseases disproportionately affecting URM, reporting on participant race is infrequent and URM are underrepresented in nephrology clinical trials. This impacts clinical practice and generalizability of findings from trials.
Racial Categories based on trial category
Ethnicity based on trial category